Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer

Conditions:   Breast Cancer;   Solid Tumor Intervention:   Drug: OBT076, a CD205-directed antibody-drug conjugate Sponsor:   Oxford BioTherapeutics Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials